Clinical characteristics of patients included in this study
| Doxorubicin (51) | FUMI (30) | |||
|---|---|---|---|---|
| Response | ||||
| PD | 8 | 7 | ||
| SD | 22 | 13 | ||
| PR | 21 | 10 | ||
| Histology | ||||
| Ductal | 46 | 26 | ||
| Other | 5 | 4 | ||
| TP53 mutations | 24 | 16 | ||
| Median age | 62 (32–85) | 64 (37–82) | ||
| Median OS (mo) | 33 (7–92) | 24 (3–54) | ||
| No. relapses | 26 | 17 | ||
Abbreviations: PD, progressive disease; SD, stable disease; PR, partial response; OS, overall survival.